View Post

George Mason University breast cancer treatment patent licensed by Targeted Pharmaceuticals

In Clinical Trials by Barbara Jacoby

Source: George Mason University From: eurekalert.org A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders. The patent, secured by faculty members of George …

View Post

How TransCelerate is digitalizing patient engagement in clinical trials

In Clinical Trials by Barbara Jacoby

By: Andrew Burrows From: knect365.com Patient-facing digital technologies have the potential to serve a variety of functions in clinical trials, such as capturing clinical endpoints, engaging patients, and facilitating remote study conduct. However, these technologies are not yet accepted as mainstream research tools, and the opportunities, challenges, and facilitators associated with their implementation in clinical trials have not been fully …

View Post

Ongoing Study Will Examine Cardiac Toxicity of Breast Cancer Treatment

In Clinical Trials by Barbara Jacoby

By: Brielle Benyon From: curetoday.com Certain breast cancer treatments could lead to heart problems down the line though unanswered questions still remain, according to recent research presented at the 2019 American Society of Clinical Oncology Annual Meeting. “We see that about a third of women, after treatment ends, are still living with fatigue and reduced exercise capacity. That puts them …

View Post

Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets

In Clinical Trials by Barbara Jacoby

Source: PACT Pharma From: PR Newswire – PACT’s gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing – The company is launching clinical studies of personalized targeted immune cell therapy for patients with solid cancers PACT Pharma, a leader in the fields of cancer immunology and cell therapy in collaboration with …

View Post

Breast cancer gene mutation clinical trial to take place in Australia

In Clinical Trials by Barbara Jacoby

By: Meagan Dillon and Leah MacLennan From: abc.net.au Breast cancer is a disease that predominantly impacts women, but it is not unheard of for men to also carry a rare genetic mutation that significantly increases the risk. Helen Hicks’s husband Tony Ransom is in that category — but the Adelaide couple will not know if the mutation has been passed …

View Post

Key Trials Showcase the Utility of Neratinib in HER2+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com Given the number of prophylactic interventions that are now available, counseling patients with early-stage HER2-positive breast cancer on the benefit of extended adjuvant therapy with neratinib (Nerlynx) or considering its use in those with central nervous system metastases could be beneficial, said Michel Velez, MD. “We know that neratinib has value in the extended adjuvant …

View Post

Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma

In Clinical Trials by Barbara Jacoby

From: PR Newswire ~ Results Show Treatment with the TLPLDC Vaccine Significantly Reduced the Risk of Disease Recurrence by 50 Percent Compared to Placebo in Patients with Stage III and IV Resected Melanoma Who Completed the Primary Vaccine Series ~ TLPLDC Continues to Demonstrate a Predictable and Well-Tolerated Safety Profile with No New Safety Signals Identified ~ Data Support Plans …

View Post

Optimal Just-in-Time Service Changing the Paradigm of Cancer Trials

In Clinical Trials by Barbara Jacoby

From: businesswire.com First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America® (CTCA) are collaborating to speed patient enrollment in oncology clinical trials, enhancing patient access to potentially life-changing therapies and saving time in drug researchers’ quest to conquer …

View Post

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

In Clinical Trials by Barbara Jacoby

By: Sharon Begley From: statnews.com The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported on …

View Post

Leveraging Patient-Centric Data Analytics to Accelerate Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Crystal Black, Saama Technologies From: pharmavoice.com We are all familiar with the figures — it takes over a decade and $2.6 billion to bring a new drug to market. While these objective statistics are daunting and do give pause, almost every life science professional will agree that they don’t begin to tell the true story of the human element …